
KalVista Pharmaceuticals, Inc.
- Jurisdiction
United States - LEI
529900Q7IDA3WUGRZA51 - ISIN
US4834971032 (KALV )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
1
/ 7
Profile
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. Read full profile
Fundamentals
- Net revenue
€1.22M - Gross margin
74.3% - EBIT
-€172.97M - EBIT margin
-14,220.8% - Net income
-€173.23M - Net margin
-14,242.4%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
Name | Title | Transaction Date | Shares | Price | Value |
---|---|---|---|---|---|
Audhya Paul K. | CHIEF MEDICAL OFFICER |
|
|
|
|
Sweeny Nicole | Chief Commercial Officer |
|
|
|
|
Yea Christopher | CHIEF DEVELOPMENT OFFICER |
|
|
|
|
Audhya Paul K. | CHIEF MEDICAL OFFICER |
|
|
|
|
Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
|
|
|
|